Drug Trial Radar · NCT03931928
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
Sep 10, 2019
Primary completion
May 3, 2021
Study completion May 3, 2021
Sponsor
- Lead sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen remains an important treatment option for patients before menopause and those patients after menopause who cannot be treated with aromatase-inhibitors. Nonetheless, a considerable amount of patients suffer a relapse of their cancer while on treatment with tamoxifen. Tamoxifen is a drug that is metabolized to a variety of compounds by the human liver, and the most important antihormonally active metabolite is called (Z)-Endoxifen. It is known that patients who have a reduced or absent activity of the drug-metabolizing enzyme CYP2D6 have lower levels of (Z)-Endoxifen. Furthermore, it has been observed that patients on tamoxifen therapy who have absent CYP2D6 activity are at a 2-fold increased risk for disease recurrence, and patients with lower CYP2D6 compared to patients with normal CYP2D6 activity still have a 1.4-fold increased risk for disease recurrence. This trial will include patients who are already on tamoxifen therapy for at least 3 months and is designed to show that in patients with absent or low CYP2D6 activity, (Z)-Endoxifen supplementation - that is giving (Z)-Endoxifen in addition to tamoxifen for the study period of 42 days - can increase blood levels of (Z)-Endoxifen to therapeutic concentrations. It is planned to included 504 patients in this blinded, randomized trial, which will have a placebo group (receiving no (Z)-Endoxifen) and two intervention groups that will receive 0, 1.5 or 3 mg (Z)-Endoxifen depending on their CYP2D6 genetics or their (Z)-Endoxifen levels at the start of the study. The trial is not designed to evaluate outcome measures (that is recurrence or survival rates) of (Z)-Endoxifen supplementation in tamoxifen treated patients, but will document the safety of the combined administration of tamoxifen and (Z)-Endoxifen.
Conditions
- Breast Cancer
- DCIS
Interventions
(Z)-Endoxifen supplementation according to genotypeDrug
Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
(Z)-Endoxifen supplementation according to plasma levelsDrug
Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, \> 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and \> 25 nM receive 0 mg (Placebo)
Primary outcomes
What the sponsor says the trial is designed to measure.
- (Z-)endoxifen plasma concentration > 32 nMTime frame: 42 days (-2 days/+7 days)
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Gemeinschaftspraxis für Gynäkologie und Geburtshilfe Salzgitter
Salzgitter, Albert-Schweitzer-Straße 18, Germany
Zentralklinikum Suhl, Klinik für Frauenheilkunde/Geburtsmedizin, Zentrum für klinische Studien
Suhl, Albert-Schweitzer-Straße 2, Germany
Rems-Murr-Klinikum-Winnenden, Frauenklinik
Winnenden, Am Jakobsweg 1, Germany
Robert-Bosch-Krankenhaus
Stuttgart, Auerbachstr. 112, Germany
Onkologische Gemeinschaftspraxis Hildesheim, Gynäkologie
Hildesheim, Bahnhofsplatz 5, Germany
Johanniter-Krankenhaus Stendal, Klinik für Frauenheilkunde und Geburtshilfe
Stendal, Bahnhofstr. 24-26, Germany
Klinikum Magdeburg, Klinik für Hämatologie/Onkologie
Magdeburg, Birkenallee 34, Germany
Klinikum Memmingen, Brustzentrum
Memmingen, Bismarckstraße 23, Germany
Klinikum am Bruderwald Bamberg, Hämatologie/Internistische Onkologie
Bamberg, Buger Straße 80, Germany
MVZ am Klinikum am Bruderwald Bamberg
Bamberg, Buger Straße 80, Germany
Universitätsfrauenklinik Tübingen
Tübingen, Calwer Straße 7, Germany
Helios Klinikum Gifhorn, Interdisziplinäres Brustzentrum
Gifhorn, Campus 6, Germany
ViDiA Christliche Kliniken Karlsruhe, Frauenklinik
Karlsruhe, Diakonissenstr.28, Germany
Klinikum Quedlinburg, Frauenklinik
Quedlinburg, Ditfurter Weg 24, Germany
Klinikum Höchst Frankfurt am Main, Klinik für Gynäkologie und Geburtshilfe
Frankfurt am Main, Gotenstr. 6-8, Germany
Evangelisches Diakonie-Krankenhaus Bremen, Frauenklinik
Bremen, Gröpelinger Heerstraße 406-408, Germany
Onkologische Gemeinschaftspraxis Brudler-Heinrich-Bangerter Augsburg
Augsburg, Halderstraße 29, Germany
medius Klinik Ostfildern-Ruit, Brustzentrum
Ostfildern, Hedelfingerstraße 166, Germany
Helios Universitätsklinikum Wuppertal GmbH, Brustzentrum
Wuppertal, Heusnerstraße 40, Germany
Klinikum Esslingen, Klinik für Frauenheilkunde, Brustzentrum
Esslingen am Neckar, Hirschlandstraße 97, Germany
SRH Kliniken Sigmaringen, Gynäkologie und Geburtshilfe
Sigmaringen, Hohenzollerstr. 40, Germany
Harz-Klinikum Wernigerode, Abteilung Gynäkologie und Geburtshilfe
Wernigerode, Ilsenburger Straße 15, Germany
Klinikum Passau, Gynäkologische Onkologie
Passau, Innstraße 76, Germany
St. Johannes Hospital Dortmund, Klinische Forschung
Dortmund, Johannesstraße 9-17, Germany
Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe
Bottrop, Josef-Albers-Straße 70, Germany
Universitätsfrauenklinik Mainz, Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde
Mainz, Langenbeckstr. 1, Germany
Onkozentrum Dresden, Fachärzte für Innere Medizin, Hämatologie und Internistische Onkologie
Dresden, Leipziger Straße 120, Germany
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Klinik für Gynäkologie und gyn. Onkologie
Wiesbaden, Ludwig-Erhard-Straße 100, Germany
Luisenkrankenhaus Düsseldorf GmbH & Co. KG, Brustzentrum
Düsseldorf, Luise-Rainer-Straße 6-10, Germany
Marienhospital Witten, Brustzentrum
Witten, Marienplatz 2, Germany
Städtisches Klinikum Karlsruhe, Frauenklinik
Karlsruhe, Moltkestr. 90, Germany
Kliniken der Stadt Köln, Brustzentrum Köln-Holweide
Cologne, Neufelder Straße 32, Germany
Diakonissen-Krankenhaus Speyer, Klinik für Gynäkologie und Geburtshilfe
Speyer, Paul-Egell-Straße 33, Germany
Klinikum Ludwigsburg, Frauenklinik
Ludwigsburg, Posilipostraße 4, Germany
DRK Kliniken Berlin-Köpenick, Frauenklinik
Köpenick, Salvador-Allende-Straße 2-8, Germany
MVZ Eggenfelden, Gynäkologische Onkologie
Eggenfelden, Schellenbruckerstr. 15, Germany
Klinikum am Steinenberg Reutlingen, Frauenklinik
Reutlingen, Steinenbergstr. 31, Germany
SRH Wald-Klinikum Gera GmbH, Klinik für Frauenheilkunde/Geburtsmedizin
Gera, Straße Des Friedens 122, Germany
Elisabeth Krankenhaus Kassel gGmbH, Brustzentrum
Kassel, Weinbergstr. 7, Germany
MVZ am Schlosssee Gifhorn
Gifhorn, Zur Allerwelle 4, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.